A multi-media tool to illustrate the impact of respiratory disease on other body systems. Press play and click the icons to learn more. Each section has an introduction in the top left icon.
Tobacco dependency is a long-term relapsing condition that usually starts in childhood. This resource provides valuable information on how you can support patients to quit
Completing the VBA will tell you your patient’s self-reported tobacco status – an important first step.
Evidence-based guide for healthcare professionals who want to do better in treating tobacco dependency
Chronic obstructive pulmonary disease (COPD) is a preventable and treatable condition that remains a major cause of morbidity and mortality worldwide. The impact on patients, families and healthcare systems is huge, yet many exacerbations, hospitalisations and disease progression can be prevented if the fundamentals of care are delivered consistently, including early and accurate diagnosis.
Winter brings predictable surges in respiratory illness and pressure across urgent and emergency care. This paper sets out a practical, primary care-led framework to reduce avoidable demand by acting earlier on respiratory risk. We describe seven interventions:
The UK has the largest market for vapes in Western Europe. There has been a rapid increase in use over the last decade and, whilst this has now been stabilised in adults, there has been a sharp rise in usage in 18-24-year-olds from 2020, coinciding with the introduction of disposable and flavoured vapes into the UK, which have been popular and attractive to children and young people. In this position statement we outline the background, key issues and PCRS position on CYP and vaping. As part of this, the Primary Care Respiratory Society (PCRS) advocates that:
The Primary Care Respiratory Society (PCRS) advocates that:vaping should be discouraged among children and young people;accurate information should be available for them, their families, schools and health professionals around the potential risks of vaping, in terms of a gateway product for other addictive behaviours; andthat long-term safety data should be available for this age group in regulated products.